Equilibra Bioscience

Executive Summary

Equilibra Bioscience is a clinical-stage biopharmaceutical company dedicated to developing a novel anti-activated Protein C (APC) monoclonal antibody for treating inherited and acquired bleeding disorders, including Hemophilia A and B. Founded in 2018 and headquartered in San Diego, the company addresses a significant unmet need in hemophilia care, where current treatments often require frequent infusions and can lead to inhibitor development. By targeting APC, Equilibra aims to enhance thrombin generation, thereby restoring hemostasis more effectively. This approach has the potential to provide a universal therapy for hemophilia patients regardless of inhibitor status, offering a differentiated mechanism that could improve patient outcomes and quality of life. Equilibra is currently in Phase 1 clinical development, having advanced its lead candidate through preclinical studies that demonstrated promising safety and efficacy profiles. The company's progress positions it well within the competitive landscape of next-generation hemophilia therapies. Key upcoming milestones include completion of Phase 1 dose-escalation and expansion cohorts, which will inform the design of Phase 2 trials. While the company is private and has not disclosed funding specifics, its focus on a validated target and clear clinical path suggests potential for partnerships or further investment as data matures. The near-term outlook hinges on successful Phase 1 data readout, which could de-risk the program and unlock value.

Upcoming Catalysts (preview)

• Q4 2026Completion of Phase 1 dose-escalation and initial safety/efficacy data70% success
• H2 2027Initiation of Phase 2 clinical trial for hemophilia patients60% success
• TBDPotential licensing or partnership deal for ex-US rights40% success